ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)

Yang, Yu; Sun, Juxian; Wu, Mengchao; Lau, Wan Yee; Zheng, Shusen; Wang, Xue-Hao; Chen, Xiaoping; Fan, Jia; Dong, Jiahong; Cai, Jianqiang; Chen, Minshan; Chen, Yongjun; Cheng, Zhangjun; Dai, Chaoliu; Shan, Jianzhen; Du, Cheng-You; Fang, Chihua; Hu, Heping; Ji, Zhili; Jia, Weidong; Li, Gong; Li, Jing; Li, Jiangtao; Liu, Chang; Liu, Fubao; Ma, Yong; Mao, Yilei; Niu, Zuoxing; Shen, Jie; Shi, Jie; Shi, Xuetao; Song, Wenjie; Sun, Hui-Chuan; Tan, Guang; Tao, Ran; Wang, Xiaohu; Wen, Tianfu; Wu, Liqun复旦大学; 安徽医科大学; 华中科技大学; 吉林大学; 南方医科大学; 南京大学; 青岛大学; 清华大学; 上海交通大学; 哈尔滨医科大学; 四川大学; 浙江大学; 郑州大学; 西安交通大学; 中国医科大学; 中国医学科学院; 中山大学; 中国科学院; 中国医学科学院北京协和医院; 6; 1; 5
Liver Cancer2022-12DOI: 10.1159/000526038
9被引13阅读
引用收藏
分享

摘要

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)" based on current clinical studies and clinical medication experience for reference in China. Key Messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.

学科与关键词

关键词
Hepatocellular carcinomaImmune checkpoint inhibitorsConsensus
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Liver Cancer
发表日期
2022-12
卷期
第 11 卷, 第 6 期
页码
511-526
DOI
10.1159/000526038
期刊等级
1区
成果收录
SCIE

作者

  • Y

    Yang, Yu (第一作者)

  • S

    Sun, Juxian

查看全部 57 位作者收起作者
  • W

    Wu, Mengchao

  • L

    Lau, Wan Yee

  • Z

    Zheng, Shusen

  • W

    Wang, Xue-Hao

  • C

    Chen, Xiaoping

  • F

    Fan, Jia

  • D

    Dong, Jiahong

  • C

    Cai, Jianqiang

  • C

    Chen, Minshan

  • C

    Chen, Yongjun

  • C

    Cheng, Zhangjun

  • D

    Dai, Chaoliu

  • S

    Shan, Jianzhen

  • D

    Du, Cheng-You

  • F

    Fang, Chihua

  • H

    Hu, Heping

  • J

    Ji, Zhili

  • J

    Jia, Weidong

  • L

    Li, Gong

  • L

    Li, Jing

  • L

    Li, Jiangtao

  • L

    Liu, Chang

  • L

    Liu, Fubao

  • M

    Ma, Yong

  • M

    Mao, Yilei

  • N

    Niu, Zuoxing

  • S

    Shen, Jie

  • S

    Shi, Jie

  • S

    Shi, Xuetao

  • S

    Song, Wenjie

  • S

    Sun, Hui-Chuan

  • T

    Tan, Guang

  • T

    Tao, Ran

  • W

    Wang, Xiaohu

  • W

    Wen, Tianfu

  • W

    Wu, Liqun

  • X

    Xia, Jinglin

  • X

    Xiang, Bang-De

  • Y

    Yan, Maolin

  • Y

    Ying, Mingang

  • Z

    Zhang, Ling

  • Z

    Zhang, Xuewen

  • Z

    Zeng, Zhao Chong

  • Z

    Zhang, Yubao

  • Z

    Zhang, Zhiwei

  • Z

    Zhou, Jie

  • Z

    Zhou, Cuncai

  • Z

    Zhou, Jun

  • Z

    Zhou, Ledu

  • Z

    Zhou, Xinmin

  • Z

    Zhu, Ji

  • Z

    Zhu, Zhenyu

  • Z

    Zhang, Qi

  • L

    Li, Qiu

  • C

    Cheng, Shuqun

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417